Watch sustainability champions reveal key solutions, innovations accelerating India's SDGs at ‘The Sustainability 100+ Dialogues 2021’-Haryana Roundtable on March 5 at 12pm

Cipla to acquire US inhaler-maker for Rs 1,000 crore

The acquisition will help Cipla to boost manufacturing capabilities in the US along with getting some ANDA pipeline in the future.

September 25, 2020 / 03:38 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Yatin Mota – CNBC AWAAZ

Pharma Major Cipla is all set to announce an acquisition shortly in the US market, two sources familiar with the development on the condition of anonymity told CNBC Awaaz.

Cipla according to sources is said to have completed due diligence of a company specialising in respiratory and inhaler portfolio.

The acquisition is also said to boost Cipla's business in the US especially a segment which caters to the US government orders in COVID times.

"Cipla has completed due diligence of a company in US and the acquisition size could be Rs 700-1,000 crore in value. Cipla is most likely to close the deal in a months’ time," said one of the sources mentioned above.

Close

The acquisition will help Cipla to boost manufacturing capabilities in the US along with getting some ANDA pipeline in the future.

Cipla is looking to focus on the US Markets with increased drug approval pipeline and inorganic growth opportunities especially having manufacturing facilities in the US.
CNBC Awaaz
TAGS: #Cipla
first published: Sep 25, 2020 03:38 pm

stay updated

Get Daily News on your Browser
Sections